[
  {
    "ts": null,
    "headline": "AstraZeneca: Oncology Dominance Justifies New All-Time Highs",
    "summary": "AstraZeneca hit a 2026 high on strong oncology/cardiovascular sales.",
    "url": "https://finnhub.io/api/news?id=37fedf41221f724240bb6e5a39b561db6df5999f1666745993872e232235f2b3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768039200,
      "headline": "AstraZeneca: Oncology Dominance Justifies New All-Time Highs",
      "id": 138056039,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662733/image_1357662733.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca hit a 2026 high on strong oncology/cardiovascular sales.",
      "url": "https://finnhub.io/api/news?id=37fedf41221f724240bb6e5a39b561db6df5999f1666745993872e232235f2b3"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story",
    "summary": "What Is Driving the Updated Fair Value for Bristol Myers Squibb? The recent shift in Bristol Myers Squibb’s fair value estimate from US$53.55 to US$56.26 per share reflects analysts weighing improving sentiment toward large drugmakers against mixed views on the company’s own positioning. On one hand, some research points to a sector coming out of a cyclical trough, with better macro conditions, more FDA approvals, stronger clinical data, and increased M&A activity lifting expectations for...",
    "url": "https://finnhub.io/api/news?id=cdbcbf98843de3f0a2d116bc4edfefd7fceef532fbc995ab82b6c56a19058b4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768010954,
      "headline": "How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story",
      "id": 138052565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "What Is Driving the Updated Fair Value for Bristol Myers Squibb? The recent shift in Bristol Myers Squibb’s fair value estimate from US$53.55 to US$56.26 per share reflects analysts weighing improving sentiment toward large drugmakers against mixed views on the company’s own positioning. On one hand, some research points to a sector coming out of a cyclical trough, with better macro conditions, more FDA approvals, stronger clinical data, and increased M&A activity lifting expectations for...",
      "url": "https://finnhub.io/api/news?id=cdbcbf98843de3f0a2d116bc4edfefd7fceef532fbc995ab82b6c56a19058b4e"
    }
  },
  {
    "ts": null,
    "headline": "Did UBS’s Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative?",
    "summary": "In early January 2026, UBS upgraded Bristol-Myers Squibb after highlighting its broad drug pipeline, new clinical trial initiations, and progress on products aimed at easing upcoming patent expirations. This combination of analyst confidence and visible pipeline activity underscores how Bristol-Myers Squibb is working to balance patent risks with future drug launches across oncology, cardiovascular, and neuroscience. We’ll now examine how UBS’s upgrade, anchored in confidence around...",
    "url": "https://finnhub.io/api/news?id=fc77f7ad98f542178e1fb1a6d7a4133fa5f7055db7e4d1ae448f6ff40b8551fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768007573,
      "headline": "Did UBS’s Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative?",
      "id": 138052566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In early January 2026, UBS upgraded Bristol-Myers Squibb after highlighting its broad drug pipeline, new clinical trial initiations, and progress on products aimed at easing upcoming patent expirations. This combination of analyst confidence and visible pipeline activity underscores how Bristol-Myers Squibb is working to balance patent risks with future drug launches across oncology, cardiovascular, and neuroscience. We’ll now examine how UBS’s upgrade, anchored in confidence around...",
      "url": "https://finnhub.io/api/news?id=fc77f7ad98f542178e1fb1a6d7a4133fa5f7055db7e4d1ae448f6ff40b8551fa"
    }
  }
]